Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiongzhi Tongluo formula is a Traditional Chinese Medicine (TCM) herbal preparation developed by Xiyuan Hospital of the China Academy of Chinese Medical Sciences. It is primarily investigated for the treatment of ischemic stroke, utilizing the TCM therapeutic principle of 'unblocking the collaterals' (Tongluo) to promote blood circulation and neurological recovery. The formula typically incorporates botanical components such as *Ligusticum chuanxiong* (Chuanxiong) and *Angelica dahurica* (Baizhi), which are traditionally used to treat vascular and pain-related conditions. It is currently being evaluated in exploratory clinical trials to assess its efficacy and safety in patients recovering from ischemic stroke.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiongzhi Tongluo formula.